Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, U.K.
J Med Chem. 2011 May 12;54(9):3331-47. doi: 10.1021/jm200070e. Epub 2011 Apr 13.
A survey of PDE4 inhibitors reveals that some compounds trigger intracellular aggregation of PDE4A4 into accretion foci through association with the ubiquitin-binding scaffold protein p62 (SQSTM1). We show that this effect is driven by inhibitor occupancy of the catalytic pocket and stabilization of a "capped state" in which a sequence within the enzyme's upstream conserved region 2 (UCR2) module folds across the catalytic pocket. Only certain inhibitors cause PDE4A4 foci formation, and the structural features responsible for driving the process are defined. Switching to the UCR2-capped state induces conformational transition in the enzyme's regulatory N-terminal portion, facilitating protein association events responsible for reversible aggregate assembly. PDE4-selective inhibitors able to trigger relocalization of PDE4A4 into foci can therefore be expected to exert actions on cells that extend beyond simple inhibition of PDE4 catalytic activity and that may arise from reconfiguring the enzyme's protein association partnerships.
一项对 PDE4 抑制剂的调查显示,一些化合物通过与泛素结合支架蛋白 p62(SQSTM1)结合,将 PDE4A4 诱导致细胞内聚集形成堆积焦点。我们表明,这种效应是由抑制剂占据催化口袋以及稳定“加帽状态”驱动的,在这种状态下,酶的上游保守区域 2(UCR2)模块内的一个序列折叠穿过催化口袋。只有某些抑制剂会导致 PDE4A4 焦点形成,并且负责驱动该过程的结构特征已被定义。切换到 UCR2 加帽状态会诱导酶的调节 N 端部分发生构象转变,促进负责可逆聚集体组装的蛋白质缔合事件。因此,能够将 PDE4A4 重新定位到焦点中的 PDE4 选择性抑制剂有望对细胞产生超出简单抑制 PDE4 催化活性的作用,并且可能源于重新配置酶的蛋白质缔合伙伴关系。